Download Brochure
Table of Content
Get a Price
March 2025
Principal Consultant
Reviewed By
The global peptide receptor radionuclide therapy market size is estimated at US$ 2.34 billion in 2024, is projected to grow to US$ 2.58 billion in 2025, and is expected to reach approximately US$ 6.1 billion by 2034. The market is projected to expand at a compound annual growth rate (CAGR) of 10.06% between 2025 and 2034. For the treatment of metastatic or inoperable neuroendocrine tumors (NETs), peptide receptor radionuclide therapy (PRRT) is the most preferred option. It helps to decrease disease progression or the risk of death by effectively managing tumors.
Peptide receptor radionuclide therapy (PRRT) is a targeted therapeutic strategy that targets the specific receptors located on the tumor cells. It uses radiolabeled peptides to target cancer cells, delivering cytotoxic levels of radiation. Radiolabelled meta-iodo-benzyl-guanidine (MIBG) and systemic chemotherapy are unable to provide proper treatment for inoperable and metastatic pheochromocytomas and paragangliomas (PPGLs). Thus, PRRT is the preferred treatment for them. At the same time, new radiolabeled receptor-binding somatostatin analogs are being developed for the treatment of neuroendocrine tumors. These advancements in PRRT are creating new opportunities for the development of other receptor-targeting peptides. Thus, to provide effective treatment opportunities in PRRT, numerous peptides are identified that target different types of receptors and are now demonstrating their potential in PRRT.
Peptide receptor radionuclide therapy utilizes small molecules, such as peptides and antibodies, as carriers, which are referred to as radiopharmaceuticals. With the aid of AI technology and the advancement of radiopharmaceuticals, the nature and effects of these compounds can be better understood, thereby accelerating the development of new drugs. The mechanism of action of radiopharmaceuticals can also be identified and understood by using AI. It also aids in the optimization of design by analyzing data on drug-targeted interactions. A great potential for the application of AI technology is observed in radiopharmaceutical research and development. It enhances the efficiency of research and the development of new drugs, thereby promoting advancements in nuclear medicine.
Increasing Cancer Prevalences
The prevalence rates of different types of cancer, especially neuroendocrine tumors and prostate cancer, are increasing rapidly. Thus, the demand for early detection and improved treatment options increases. Due to growing awareness of the side effects of certain treatments, the demand for new treatment options is also increasing. All these factors contribute to the adoption of PRRT. Thus, to manage the increasing rates of cancer, PRRT provides effective management with successful treatment rates. As it provides targeted action, the healthy cells are not affected. Furthermore, the use of PRRT agents like Lutetium-177 is expanding. Similarly, several new agents are being identified and utilized for further advancements in PRRT in the treatment of persistent cancers.
High Price
Though PRRT shows effective management and treatment of cancer, the high pricing limits its use by the population. Hospitals or specialized clinics must use radiopharmaceuticals and specialized equipment, which makes this treatment option expensive. This results in limited access for patients. Similarly, not all hospitals may be capable of adopting PRRT or its advanced facilities, resulting in decreased treatment options for patients. Thus, due to the high cost of PRRT, the adoption process by both patients and hospitals can be delayed.
Increasing Awareness
To effectively treat and manage various types of cancers, awareness programs and campaigns are being conducted. Various institutes, along with the government and private sectors, are also supporting these campaigns. This helps deliver important information and knowledge to the population about various rare cancers, such as neuroendocrine cancer and prostate cancer. At the same time, awareness about the limitations and side effects of traditional treatments is growing. Thus, the demand for early diagnosis and treatment options increases, which in turn leads to a higher use of PRRT. PRRT overcomes the drawbacks associated with traditional treatment options, leading to a rise in demand in the market.
For instance,
By indication type, the neuroendocrine tumor segment dominated the peptide receptor radionuclide therapy market in 2024. The use of treatment options like surgery shows decreased effectiveness against mutated neuroendocrine tumors. This led to an increased demand for the PRRT treatment option. It provided early diagnosis and improved quality treatment to the patient.
By indication type, the prostate cancer segment is projected to exhibit significant growth at a notable compound annual growth rate (CAGR) during the forecast period. The increased occurrence of prostate cancer has increased the demand for PRRT. PRRT exhibits high rates of successful treatments, thereby reducing complications associated with it and enhancing market growth.
By type of therapy, the therapeutic radiopharmaceuticals segment dominated the peptide receptor radionuclide therapy market in 2024. Therapeutic radiopharmaceuticals are used to treat various cancers, particularly those with specific mutations. It provided targeted treatment, minimizing damage to healthy cells and increasing their demand in the market.
By type of therapy, the diagnostic radiopharmaceuticals segment is anticipated to grow significantly during the forecast period. It provides the exact location of the tumor in the body, which in turn helps in better treatment opportunities. Thus, with the help of early detection, specific targeting of tumors can be carried out, enhancing the effectiveness of the treatment.
By administration route type, the intravenous segment dominated the peptide receptor radionuclide therapy market in 2024. The intravenous route provides rapid absorption and distribution of drugs in the body, resulting in a faster onset of action. The 100% drug was incorporated in blood with an accurate dose. All these factors contributed to the market growth.
By administration route type, the subcutaneous segment is expected to exhibit robust growth during the forecast period. Subcutaneous route administration is performed in various hospitals, and it can also be self-administered at home. This is because it provides ease of administration and has shown a lower risk of infection compared to IV route administration.
By end user, the hospital segment dominated the global peptide receptor radionuclide therapy market in 2024. The hospital demonstrated the presence of well-equipped facilities necessary for PRRT. They also provided the patient with a controlled setting, which made it easier to manage and monitor the side effects and any other complications associated with the cancer.
By end user, the specialized clinics segment is anticipated to grow significantly during the forecast period. The specialized clinics are staffed by experts and equipped with advanced technologies. They also provide personalized care, which increases the patient's adherence to the treatment. These factors are contributing to the market growth.
North America dominated the peptide receptor radionuclide therapy market in 2024. It consists of advanced healthcare infrastructure supported by technological advancements. At the same time, the presence of specialized staff was used to carry out the treatment, effectively minimizing the errors. All these factors combined contributed to the market's growth.
The U.S. has well-established healthcare facilities along with regulatory bodies that have approved the use of PRRT agents. Due to this reason, the implementation and use of PRRT have increased. Furthermore, the increased incidences of neuroendocrine tumors have increased the demand for PRRT in the market.
According to the data provided by the American Cancer Society, the graph estimates the number of new cases and deaths from prostate cancer in the U.S. It indicates that as the number of patients increases, the requirement for treatment options will also increase. Furthermore, researchers can focus on developing more effective treatment options, which will ultimately drive the market's growth.
Well-established hospitals and specialized clinics are continuously using PRRT treatments. The research institutes are also focusing on the development of new or innovative PRRT treatment options that the government supports. At the same time, to make this treatment available to all, the government is also providing insurance schemes.
Europe is expected to experience significant growth in the peptide receptor radionuclide therapy market during the forecast period. The strong regulatory framework plays a crucial role in the increasing adoption of peptide receptor radionuclide therapy. The increasing occurrences of tumors caused the increased approval rates of PRRT to manage and support the healthcare systems.
Germany is showing early and increasing adoption of peptide receptor radionuclide therapy, thereby enhancing market growth. The number of specialized clinics is increasing, resulting in a greater utilization of PRRT with advanced technologies. It results in effective treatment, minimizing the mortality rates.
Various hospitals and institutes in the UK are continually focusing on innovation and clinical trials for PRRT, driving market growth. It also collaborates with various companies contributing to the rapid development of PRRT. Thus, alongside all these factors, healthcare facilities also play a significant role in promoting the use of PRRT.
Asia Pacific is estimated to be a significantly growing peptide receptor radionuclide therapy market during the forecast period. The prevalence rate of neuroendocrine tumors is increasing, resulting in increased demand for PRRT treatment options. Similarly, the increased awareness has led to a rise in the acceptance rates of peptide receptor radionuclide therapy among patients.
The healthcare system in China is rapidly developing and adopting various new treatment options and technologies. This has increased the number of specialized clinics that facilitate the use of new therapies, such as PRRT, and has led to higher successful treatment rates. Thus, the demand for this is rising, driving market growth.
The occurrence of cancer has caused a rise in the demand for new treatment options like PRRT. Thus, hospitals and specialized clinics are adopting PRRT to offer more effective treatment options. At the same time, the government and private sectors are investing in enhancing access to treatments like PRRT.
In March 2025, Mohammad Eslami, the head of the Atomic Energy Organization of Iran (AEOI), announced that on the anniversary of National Nuclear Technology Day on April 08, they will reveal new radiopharmaceuticals. He further stated that the country had achieved more than 100 scientific, industrial, and technological milestones by March 20, 2025; this indicated that his organization is resolute in implementing the Comprehensive Nuclear Industry Strategy in the 2041 outlook.
In March 2025, Dr. Suzuki, an Assistant Professor at Chiba University, stated that the molecular design of their synthesized astatine-211 (211At) -labeled peptide drug can be used for developing other 211At-labeled radiopharmaceuticals. He further mentioned that they believe their approach could bring new advances in treating refractory cancers, including melanoma.
By Indication
By Type of Therapy
By Administration Route
By End User
By Region
March 2025
March 2025
March 2025
March 2025
Book a Consultation